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Abstract
Background: Positron emission tomography (PET) has a potential improvement for staging and
radiation treatment planning of various tumor sites. We analyzed the use of 18F-fluorodeoxyglucose
(FDG)-PET/computed tomography (CT) images for staging and target volume delineation of
patients with head and neck carcinoma candidates for radiotherapy.
Methods: Twenty-two patients candidates for primary radiotherapy, who did not receive any
curative surgery, underwent both CT and PET/CT simulation. Gross Tumor Volume (GTV) was
contoured on CT (CT-GTV), PET (PET-GTV), and PET/CT images (PET/CT-GTV). The resulting
volumes were analyzed and compared.
Results: Based on PET/CT, changes in TNM categories and clinical stage occurred in 5/22 cases
(22%). The difference between CT-GTV and PET-GTV was not statistically significant (p = 0.2)
whereas the difference between the composite volume (PET/CT-GTV) and CT-GTV was
statistically significant (p < 0.0001).
Conclusion: PET/CT fusion images could have a potential impact on both tumor staging and
treatment planning.
Background
In squamous cell carcinoma of the head and neck, defini-
tive radiotherapy (RT) provides improved disease control
and survival rates through high dose radiation and con-
current administration of systemic drugs. The recent intro-
duction of sophisticated technology, like intensity
modulated radiotherapy (IMRT), promises to improve the
cost/benefit ratio of therapy further [1,2].
The precise identification of tumor volume remains an
open issue: tumor dose escalation and sparing of normal
tissue requires a precise identification of the extension of
the disease in individual patients. For these reasons, radi-
ation oncologists are interested investigating functional
imaging such as positron emission tomography (PET) in
particular with 18F-fluorodeoxyglucose (FDG) that pro-
vides improved staging, treatment response identification,
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[3,4], including head and neck carcinoma [5,6]. FDG-PET,
however, requires careful correlation with structural
images for precise tumor localization because of lack of
anatomical information. FDG-PET images can be directly
incorporated into CT-based RT planning through a variety
of image registration strategies [7,8]. This allows radiation
oncologists to use the complementary strengths of func-
tional (PET) and structural imaging (CT) co-registered in
a single image set.
The purpose of this study was to investigate the potential
impact of using PET/CT image fusion for the management
of patients with head and neck carcinoma. Specifically, we
analyzed how PET/CT may change the clinical stage and
the delineation of gross tumor volume (GTV) for radia-
tion treatment planning.
Methods
Patients characteristics
Twenty-two consecutive patients with primary head and
neck carcinoma were selected for radiotherapy after dis-
cussion in multidisciplinary conference and obtaining
informed consent following the rules of our institution.
Patients with Karnofsky performance status < 80/100,
tumor location in the salivary glands or unknown primary
site, evidence of distant metastases at initial staging, and
need for surgical procedures were excluded from this
study. Clinical characteristics of these patients are summa-
rized in Table 1. All patients underwent routine workup
including clinical examination, fiber-endoscopy, contrast-
enhanced CT of the head and neck district, chest X-rays,
and liver ultrasound (US). The clinical stage was defined
according to the 2002 American Joint Committee on Can-
cer-International Union Against Cancer (AJCC-UICC)
classification [9]. No patients were candidates for curative
surgery. Fifteen patients were candidates for combined
radiotherapy and platinum-based chemotherapy and 7
patients for radiotherapy alone.
Image acquisition and fusion
All patients underwent routine CT simulation in supine
position, immobilized with head-rest and customized
thermoplastic mask by using the scanner GE Prospeed
(General Electric, Milwaukee, WI, USA). The planning
volume was scanned from the top of the skull to the mid-
thorax. The CT simulation images were subsequently
fused to the hybrid PET/CT images by means of a dedi-
cated radiation treatment planning system (RTPS) image
fusion tool (Syntegra, Philips Medical System, Eindhoven,
The Netherlands) based on a mutual information algo-
rithm.
PET/CT was performed within 5 working days from the
CT simulation scan and after at least 21 days from the
tumor biopsy. In order to assure a reproducible patient
setup, the same immobilization device used during CT
simulation as well as a flat-panel carbon fiber composite
table insert were also used for PET/CT acquisition.
Images were acquired by the Biograph 16 HI-REZ PET/CT
scanner (Siemens, Hoffman Estates, IL, USA). The PET
component is a high-resolution scanner with a spatial res-
olution of 4.7 mm and no septa, thus allowing 3D-only
acquisitions. The CT component is the Somatom Sensa-
tion sixteen-slice CT (Siemens, Hoffman Estates, IL, USA).
The CT scanner is used both for attenuation correction of
PET data and for localization of FDG uptake in PET
images. All patients were advised to fast for at least 6 hours
prior to PET/CT examination. After injection of about 5
MBq of FDG per kg of body weight, patients were rested
for a period of about 60 minutes in a comfortable chair.
Emission images ranging from the proximal femur to the
base of the skull were acquired for 2–3 minutes per bed
position. Field of view was of 50 cm with a matrix of 512
× 512 pixels for CT and of 128 × 128 for PET. The proc-
Table 1: Characteristics of study population.
Characteristics N.
Patients 22
Age (years)
Median 59
Range 43–76
Gender
Male 18
Female 4
Tumor subsite
Oral Cavity 2
Oropharynx 6
Hypopharynx 6
Larynx 2
Nasopharynx 4
Paranasal sinuses 2
Histology
Squamous cell 18
Undifferentiated 3
Adenocarcinoma 1
Pathologic AJCC stage
I 4
II 5
IIB 2
III 3
IVA 7
IVB 1
Pathologic TNM categories
T1, T2, T2b, T3, T4a N0 M0 13
T2, T4a N1 M0 2
T2 N2a M0 1
T2, T3, T4a N2b M0 5
T4 N3 M0 1
Abbreviations: AJCC: American Joint Committee on Cancer; T: 
tumor extension; N: lymph-nodal disease; M: distant metastasis.Page 2 of 6
(page number not for citation purposes)
Radiation Oncology 2008, 3:29 http://www.ro-journal.com/content/3/1/29essed images were displayed in coronal, transverse, and
sagittal plans. After image acquisition, PET/CT data sets
were sent to the treatment planning system Pinnacle
(Philips, Adac Laboratories, Milpitas, CA, USA) through
local network.
Tumor staging and target volume delineation
The clinical staging was analyzed by comparing the PET/
CT with the CT alone findings. For PET image interpreta-
tion, a focal FDG uptake was considered as positive when
the activity was significantly above the expected back-
ground and could not be explained by a normal structure.
A fixed image intensity threshold method (40% of maxi-
mum intensity) was used to outline the PET-GTV for the
primary tumor and the involved nodal sites [10].
The target volumes were outlined by two radiation oncol-
ogists with specific experience in head and neck tumors
management according to the guidelines of the Interna-
tional Commission on Radiation Units and Measure-
ments Report 62 [11]. They were not blinded to each
other and outlined together the contours achieving a final
consensus. GTVs were contoured on CT images obtaining
CT-GTV, PET (PET-GTV), and PET/CT images (PET/CT-
GTV). The PET/CT-GTV included both PET and CT infor-
mation. The clinical target volume (CTV), for treatment
purpose, was identified as the PET/CT-GTV with an addi-
tional 5 mm margin and included also the regional lymph
nodes. The planning target volume (PTV) was subse-
quently semi-automatically outlined giving an additional
5 mm margin to the CTV.
For clinical purposes, we always considered the PET image
as an additional information to CT image either for tumor
staging or for target contouring for treatment planning.
Statistical analysis
The difference between PET-GTV and CT-GTV and
between PET/CT-GTV and CT-GTV were analyzed by Wil-
coxon signed rank test. A p value of less than 0.05 was con-
sidered to be statistically significant. Data were reported as
mean ± 95% confidence interval.
The following additional volumes were considered for the
statistical analysis (Figure 1):
-the volume identified by PET but not by CT (PEToutCT),
-the volume identified by CT but not by PET (CToutPET),
-the common volume of CT and PET (CT&PET).
Results
Tumor staging
PET/CT imaging lead to a change in the TNM categories
and in the clinical stage in 5/22 (22%) cases compared to
CT alone (Table 2). T-stage changed in 3 of 22 (14%) and
N-stage in 2 of 22 cases (10%) N0 at CT. In one of these
cases (case 3 in Table 2), the PET/CT finding was con-
firmed by fine needle agobiopsy (FNA). This patient was
affected by squamous cell carcinoma of the left hypopha-
ryngeal wall with 1 cm in diameter lymph node in the left
level II had intense FDG uptake suggestive for nodal
involvement with potential upstaging from N0 to N1. In
such a case, biopsy did not find the presence of tumor
cells and the patient was considered as N0. In another case
of hypopharyngeal cancer (case 5 in Table 2), a lymph
node in the mediastinum, suggestive for metastatic dis-
ease, although not confirmed with biopsy by mediastinos-
copy because of medical contraindications for general
The diagram shows the volumes identified after fusion of CT and PET imagesFigure 1
The diagram shows the volumes identified after 
fusion of CT and PET images. "PET/CT-GTV" is the 
composite volume of PET and CT; "PEToutCT" is the volume 
identified by PET but not by CT; "CToutPET" is the volume 
identified by CT but not by PET; "CT&PET" is the common 
volume of PET and CT.
Table 2: Change of clinical stage related to PET/CT in 5/22 
patients (22%).
Case N. Site CT stage PET/CT stage
1 Oropharynx T1 N0 M0 T2 N0 M0
Stage I Stage II
2 Nasopharynx T3 N2b M0 T4 N2b M0
Stage III Stage IVA
3 Hypopharynx T1 N0 M0 T1 N1 M0
Stage I Stage III
4 Hypopharynx T2 N0 M0 T2 N1 M0
Stage II Stage III
5 Hypopharynx T3 N2b M0 T4 N2b M1
Stage IVA Stage IVC
Abbreviations:
CT: computed -tomography;
PET/CT: positron emission tomographyPage 3 of 6
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ical stage changed from M0 to M1 and consequently the
treatment intent from curative to palliative. This patient
received radiotherapy combined with chemotherapy and
died with intra-thoracic and liver metastases 8 months
later.
Target volumes
As for the volume delineation, PET-GTV was smaller than
CT-GTV (17.2 cc, with a standard deviation of 16.8 cc vs.
20.0 cc, with a standard deviation of 17.8 cc) with a mean
difference of 2.8 cc, that was not statistically significant (p
= 0.2). However, PET/CT-GTV (26 cc), that was used for
clinical purposes, was significantly greater than CT-GTV
(p < 0.0001). These volumes had a mean difference of 6
cc (Figure 2). The analyzed volumes for all patients are
reported in Table 3.
The mean and range values of the additional volumes ana-
lyzed to compare PET/CT and CT alone are reported in
Table 4 and Figure 1. In particular, the mean PEToutCT
volume was 27% of the mean CT-GTV and resulted ≥
10%, i.e. 2 cc, larger than the mean CT-GTV in 13/22
patients (59%).
Discussion
The use of FDG-PET/CT prior to treatment has gained
interest in the radiation oncology community in relation
to a potential improvement of tumor staging, optimiza-
tion of treatment strategy, and better delineation of target
volume[12].
The advantage of PET/CT fusion has been already reported
for staging and RT planning of non-small cell lung cancer
in a number of literature studies [13] and preliminary data
on the role of PET/CT fusion are available for other tumor
locations such as esophagus, rectum, anal canal, and pan-
creas [14-16].
Recent results in a limited number of studies are available
about the role of PET/CT imaging for staging and RT treat-
Axial FDG-PET/CT image of a patient with nasopharyngeal undifferentiated carcinomaFigure 2
Axial FDG-PET/CT image of a patient with nasopha-
ryngeal undifferentiated carcinoma. The computed 
tomography gross tumor volume (CT-GTV) and the positron 
emission tomography (PET)-GTV are highlighted with red 
and light blue contours, respectively. For treatment purposes 
both findings were taken into account.
Table 3: Volumes (cc) identified by CT and PET in every single 
case.
Patients Subsites CT-GTV PET-GTV PET/CT-GTV
1 Nasopharynx 17.7 30.3 36.5
2 Oral Cavity 65.9 49.0 78.7
3 Oral Cavity 16.1 22.2 25.1
4 Oropharyx 52.5 34.1 60.2
5 Hypopharynx 5.4 1.7 5.4
6 Hypopharynx 45.5 46.3 64.2
7 Hypopharynx 8.7 12.1 13.5
8 Oropharynx 35.3 20.1 36.1
9 Nasopharynx 6.3 3.5 6.4
10 Paranasal sinus 17.4 8.0 17.8
11 Oropharynx 2.1 4.5 5.3
12 Larynx 9.8 1.7 9.8
13 Nasopharynx 37.0 57.8 60.3
14 Oropharynx 6.0 2.6 6.2
15 Oropharynx 28.9 11.2 29.4
16 Oropharynx 6.5 17.3 19.8
17 Hypopharynx 13.4 4.7 13.9
18 Hypopharynx 1.3 4.0 5.0
19 Nasopharynx 17.8 15.2 20.3
20 Paranasal Sinus 40.8 34.7 61.8
21 Hypopharynx 7.1 8.9 11.9
22 Larynx 19.5 6.5 19.5
Table 4: Volumes (cc) identified after fusion of PET and CT 
images.
Volumes Mean Range Confidence Interval
PET/CT-GTV 26.0 5.0–78.7 15.9–36.2
PEToutCT 5.5 0.0–21.2 2.4–8.7
CToutPET 8.1 0.7–28.0 4.4–11.8
CT&PET 11.2 0.4–36.2 6.2–16.2
Abbreviations: PET/CT-GTV: the composite volume between PET 
and CT; PEToutCT: the volume identified by PET but not by CT; 
CToutPET: the volume identified by CT but not by PET; CT&PET: the 
common volume of the two image modalities (CT and PET).Page 4 of 6
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noma [17-20].
In our experience, the primary tumor was identified by
PET/CT in all 22 patients with a change for both TNM cat-
egories and clinical stage in 22% of them. Similar results
were reported by Koshy and Paulino [21]. In their study,
they enrolled 36 patients and found that PET/CT fusion
altered the TNM categories in 38% and the clinical stage
in 14% of the patients. Also in a recent study published by
Wang et al. [22], the CT-based staging was changed by
PET/CT in 16/28 cases (57%).
In the second part of our study, we evaluated how PET/CT
may influence the delineation of GTV considering the PET
information as additional to that of CT. In our experience,
the tumor volume identified by PET only was smaller than
CT-GTV but the co-registration of PET and CT images
allowed the identification of a potentially greater GTV,
used for clinical purposes, similarly to what observed by
Schwartz et al. [2] in 19 patients. In our series, the PET-
GTV was smaller than the CT-GTV but the difference (2.8
cc) was not statistically significant (p = 0.2), whereas
Heron et al. [18] found a significant decrease (p = 0.002)
of PET-based GTV compared to CT-based GTV with a
median difference of 22.3 cc in a group of 21 patients.
Similarly, Paulino et al. [23] observed that PET-GTV was
smaller in 75% of 40 patients, with a median difference
between CT-GTV and PET-GTV of 16.9 cc. The finding of
CT-GTV larger than PET-GTV in our as well as in other
published series may be related to areas of necrosis inside
the tumor identified by CT but not by PET because of lack
of FDG uptake of the necrotic tissue.
A possible criticism to most of these studies, including the
present one, is the uncertain correlation of the PET/CT
findings with the real tumor extension that can only be
precisely assessed on the surgical specimen. In our study,
only 1 case had a cytological correlation: PET/CT overesti-
mated the lymph nodal tumor extension. The correlation
between tumor delineation on PET compared to pathol-
ogy was investigated by Halpern et al. [24] who compared
FDG-PET/CT image fusion with histopathology on 49
patients. A patient-by-patient analysis yielded a sensibility
of 88%, a specificity of 78%, and an accuracy of 86% for
PET/CT compared to pathology. In another study, Daisne
et al. [25] compared the GTV identified by PET/CT with
the pathology specimen of 9 patients affected by head and
neck carcinoma. The investigators observed that the GTV
delineated on the pathology specimen was in average
smaller than that identified by PET/CT. In particular, PET/
CT underestimated part of the macroscopic tumor exten-
sion in the mucosa of the contralateral larynx but, on the
other hand, overestimated the infiltration of the cartilage,
the extra laryngeal and pre-epiglottic space, and the thy-
roid gland.
In the article of Daisne et al. [25], the average GTV identi-
fied only by PET corresponded to 14% of the GTV con-
toured from CT images for oropharyngeal and to 13% for
laryngeal and hypopharyngeal tumor locations. In our
study, such value was as high as 27%. This fact should be
carefully taken into consideration because the inclusion
of this mismatched volume in the target volume could
reduce the incidence of geographical missing. This addi-
tional volume identified only by PET may have an even
greater importance when using highly conformal tech-
niques like intensity modulated radiation therapy
(IMRT), stereotactic radiotherapy, and charged particle
therapy.
A relevant still open issue is the consistency of target
delineation on PET images. In the available literature,
GTV contouring with FDG-PET has varied, but has typi-
cally been based on standard uptake value (SUV). In the
present study, we adopted the 40% of the SUV similarly to
what proposed by other authors for lung and also head
and neck tumors [10,26,27].
Conclusion
The present study shows that FDG-PET/CT images for pri-
mary head and neck carcinoma had a potential impact on
both tumor staging and treatment planning. A clinical
stage variation was observed in 22% of cases and a signif-
icant greater GTV was detected thanks to PET/CT images.
Based on our data as well as the other literature results, the
future scenario of imaging for radiotherapy of head and
neck tumors may include the use of functional imaging
such as FDG-PET/CT with the aim to characterize the bio-
logical features of the tumor and optimize the use of
highly conformal and biologically effective radiation
treatment.
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